The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to ABS Corporation, a veterinary drug manufacturer in Omaha, Nebraska, after a January 2026 inspection identified significant CGMP violations involving OOS investigations, incoming component testing, and process validation.